汉森制药(002412) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥226,177,460.31, representing a 13.86% increase compared to ¥198,637,113.99 in the same period last year[8] - Net profit attributable to shareholders was ¥36,393,214.40, up 23.22% from ¥29,536,060.34 year-on-year[8] - Basic earnings per share rose to ¥0.1230, reflecting a 23.25% increase from ¥0.0998 in the same period last year[8] - The company expects net profit attributable to shareholders for the first half of 2018 to be between ¥55,955,800 and ¥69,278,600, representing a growth of 5.00% to 30.00% compared to the same period last year[21] Cash Flow - The net cash flow from operating activities improved significantly to ¥12,881,994.23, a 190.11% increase from a negative cash flow of ¥14,296,361.17 in the previous year[8] - Net cash flow from operating activities increased by ¥27,178,355.40, a growth of 190.11%, attributed to higher sales collections compared to the same period last year[16] - Net cash flow from investing activities increased by ¥27,297,064.09, a growth of 76.07%, mainly due to a significant reduction in cash payments for fixed assets and intangible assets[17] - Net cash flow from financing activities decreased by ¥2,725,700.45, a decline of 279.14%, primarily due to a significant reduction in bank borrowings compared to the previous year[17] - The net increase in cash and cash equivalents rose by ¥51,749,719.04, a growth of 101.16%, driven by increases in operating and investing cash flows[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,734,140,257.47, a 1.98% increase from ¥1,700,409,524.23 at the end of the previous year[8] - The net assets attributable to shareholders increased by 2.98% to ¥1,255,624,552.07 from ¥1,219,231,337.67 at the end of the last year[8] - Accounts receivable increased by ¥66,645,342.80, a growth of 41.82%, mainly due to increased sales revenue and reduced customer payments[15] - Prepaid accounts increased by ¥2,809,871.33, a growth of 58.73%, primarily due to advance payments for materials to Shanxi Tongji Pharmaceutical Co., Ltd.[15] Profitability and Returns - The weighted average return on equity was 2.94%, up from 2.32% in the previous year, indicating improved profitability[8] - Investment income decreased by ¥4,206,580.32, a decline of 234.30%, mainly due to reduced equity method investment income from Hunan Sanxiang Bank[16] - Asset impairment losses increased by ¥2,330,051.44, a growth of 195.77%, due to increased accounts receivable and corresponding bad debt provisions[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,847[11] - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, held 42.13% of the shares[11] Other Income - The company has received government subsidies related to daily activities, resulting in an increase in other income by ¥367,256.81 compared to the previous year[16] - The company reported non-recurring gains and losses totaling ¥234,844.58 for the period[9]